Your browser is no longer supported. Please, upgrade your browser.
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own3.10% Shs Outstand43.60M Perf Week-6.46%
Market Cap1.26B Forward P/E- EPS next Y-1.38 Insider Trans-9.83% Shs Float42.28M Perf Month-19.51%
Income-51.20M PEG- EPS next Q-0.29 Inst Own64.50% Short Float3.49% Perf Quarter11.26%
Sales6.50M P/S193.94 EPS this Y56.20% Inst Trans-0.73% Short Ratio2.23 Perf Half Y487.15%
Book/sh0.86 P/B27.10 EPS next Y-18.10% ROA-69.60% Target Price32.00 Perf Year1541.55%
Cash/sh1.00 P/C23.26 EPS next 5Y- ROE-121.40% 52W Range1.16 - 30.38 Perf YTD260.28%
Dividend- P/FCF- EPS past 5Y-0.90% ROI-105.00% 52W High-23.26% Beta0.65
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin20.80% 52W Low1909.48% ATR1.66
Employees60 Current Ratio3.90 Sales Q/Q45.50% Oper. Margin- RSI (14)41.68 Volatility6.34% 6.40%
OptionableYes Debt/Eq0.28 EPS Q/Q33.60% Profit Margin- Rel Volume0.64 Prev Close22.95
ShortableYes LT Debt/Eq0.28 EarningsMay 27 BMO Payout- Avg Volume661.41K Price23.31
Recom1.40 SMA20-9.07% SMA50-6.86% SMA200106.23% Volume425,102 Change1.57%
Apr-21-21Initiated H.C. Wainwright Buy $40
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
May-07-21 08:35AM  
07:00AM  
Apr-29-21 05:02PM  
Apr-26-21 01:39AM  
Mar-18-21 06:02PM  
Mar-15-21 07:00AM  
Feb-25-21 07:00AM  
Feb-22-21 07:00AM  
Feb-10-21 07:00AM  
Jan-25-21 02:40PM  
Jan-20-21 01:25PM  
12:13PM  
10:30AM  
08:45AM  
07:32AM  
04:19AM  
Jan-19-21 04:34PM  
04:01PM  
12:10PM  
07:00AM  
Dec-28-20 11:17PM  
Dec-23-20 09:11AM  
Dec-15-20 11:26PM  
07:00AM  
Nov-16-20 04:01PM  
Nov-14-20 07:08AM  
Nov-06-20 12:00PM  
Nov-04-20 08:25AM  
07:00AM  
Oct-29-20 12:35PM  
Oct-21-20 10:46AM  
Oct-20-20 07:00AM  
Oct-14-20 10:36PM  
Oct-01-20 12:00PM  
Sep-30-20 06:40AM  
Sep-01-20 04:01PM  
Aug-13-20 12:00PM  
Aug-07-20 08:45AM  
07:00AM  
Aug-06-20 12:30PM  
Jul-08-20 08:43AM  
Jul-07-20 04:01PM  
Jun-26-20 02:30PM  
Jun-18-20 10:12AM  
Jun-17-20 10:37AM  
07:01AM  
Jun-03-20 07:00AM  
May-26-20 04:01PM  
May-12-20 10:47AM  
May-08-20 12:00PM  
May-07-20 04:01PM  
May-06-20 12:30PM  
Apr-09-20 06:13AM  
Apr-06-20 12:00PM  
Apr-01-20 11:07AM  
Mar-31-20 04:01PM  
Mar-17-20 02:46AM  
Feb-25-20 04:01PM  
Feb-24-20 07:31AM  
Feb-19-20 05:00PM  
Feb-10-20 07:00AM  
Jan-13-20 05:03PM  
Jan-10-20 07:13AM  
05:40AM  
Jan-09-20 04:27PM  
Jan-08-20 08:00AM  
Dec-24-19 12:00PM  
Dec-12-19 10:33AM  
Nov-27-19 03:23PM  
Nov-21-19 11:39AM  
Nov-18-19 05:34PM  
Nov-17-19 07:14AM  
Nov-12-19 04:01PM  
Nov-07-19 04:01PM  
Oct-31-19 04:01PM  
Oct-29-19 10:33AM  
Oct-25-19 07:12AM  
Oct-24-19 04:01PM  
Oct-17-19 09:46AM  
Oct-14-19 10:28AM  
Oct-11-19 11:46AM  
Oct-10-19 04:02PM  
Oct-09-19 07:58AM  
Oct-08-19 05:01PM  
01:42PM  
Oct-07-19 07:25AM  
Oct-06-19 10:00AM  
Oct-03-19 07:28AM  
Sep-30-19 12:15PM  
10:44AM  
Sep-28-19 06:30PM  
10:00AM  
Sep-27-19 08:15PM  
03:00PM  
12:21PM  
11:00AM  
10:36AM  
Sep-26-19 04:45PM  
04:45PM  
11:17AM  
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ali-Jackson KamilChief Legal OfficerMay 07Option Exercise10.665,41657,735149,034May 07 06:28 PM
Ali-Jackson KamilChief Legal OfficerMay 07Sale23.525,416127,392143,618May 07 06:28 PM
Ali-Jackson KamilChief Legal OfficerMay 06Option Exercise10.6615,000159,900158,618May 07 06:28 PM
Ali-Jackson KamilChief Legal OfficerMay 06Sale23.4315,000351,453143,618May 07 06:28 PM
Ali-Jackson KamilChief Legal OfficerMay 05Option Exercise10.6615,000159,900158,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 05Sale23.9815,000359,713143,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 04Option Exercise10.6615,000159,900158,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 04Sale23.6815,000355,187143,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 03Option Exercise10.6615,000159,900158,618May 05 08:04 PM
Ali-Jackson KamilChief Legal OfficerMay 03Sale24.5915,000368,818143,618May 05 08:04 PM
Ruffo FrankChief Financial OfficerApr 26Sale25.8027,339705,228151,720Apr 26 09:45 PM
Ruffo FrankChief Financial OfficerApr 23Sale26.6630,000799,660179,059Apr 26 09:45 PM
Ruffo FrankChief Financial OfficerApr 22Sale26.8430,000805,218209,059Apr 26 09:45 PM
Walker NealPresident and CEOApr 22Sale26.8430,000805,2391,192,427Apr 26 09:43 PM
Mehra AnandDirectorFeb 02Option Exercise18.3414,632268,29830,841Feb 03 05:33 PM